Furthermore, ITZ was found to downregulate tumor markers such as Ki-67 and key components of the Wnt/β-catenin signaling pathway, including Wnt-3a and β-catenin, while upregulating Axin-1 expression. The gene discussed is MKI67; the disease is neoplasm.